Polaris Biology
宸安生物
Polaris Biology (宸安生物) is a Chinese biotech company in the digital pharmaceutical R&D (ITBT) space, backed by 5Y Capital since at least 2021 as one of its portfolio companies in the "AI + biology" intersection . The company was founded by Wang Yuchong (王宇翀), who appeared as CEO alongside other 5Y-backed founders at the firm's ITBT forums in 2021 and 2022 . In May 2023, its flow cytometry mass spectrometer received medical device regulatory approval . The company sits within 5Y Capital's broader thesis on multi-omics data analysis and bioinformatics-enabled applications, where it has been grouped with firms like xbiome and NeoX as "important players" in the field .
AI-generated — may contain errors, please verify.
Coverage
May, Where Hope Springs Eternal | 5Y News Monthly
The big news from last month.
五源资本·July: Seeking Vast Possibilities | 5Y News Monthly
The big news from last month.
五源资本·From Tech to Business: New Possibilities Brought by ITBT | 5Y Talk
We spoke with five entrepreneurs about their progress and breakthroughs.
五源资本·5Y Talk | Next-Gen Computing + Experimentation: The Birth of New Application Categories
Technology, Industry, and the Future.
五源资本·5Y Capital's Xu Tian Jing: Why We're Bullish on Digital Pharmaceutical R&D | 5Y Talk
The ITBT track has a promising future ahead.
五源资本·5Y Capital's Xutian Jing: ITBT Sector Has a Promising Future, Poised to Produce a New Breed of Pharma Companies with Strong Cash-Generation Capabilities | Light View
ITBT is a long game, but when it succeeds, its contribution to human society is immense.
五源资本·
